Ticker brief
LPCN
last close
·
1 day
·
14 days
·
mkt cap
·
signals 14d
30
authors 14d
22
crowd 14d
+0.34
No price history on file for this name (likely non-equity or unlisted) — the “since then” column below stays blank.
Sentiment — last 14 days
· daily mean sentiment, 2026-10-07 → 2026-10-07 · now +0.37 (−1 bearish … +1 bullish)
Who spoke22
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @TT_stocks_ | C | -2.20 | 3 | +0.37 |
| @abc51648039 | C | -0.96 | 3 | +0.40 |
| @ineedsow | C | -2.15 | 2 | +0.20 |
| @MrGannabc | C | -1.55 | 2 | +0.62 |
| @Greatstockpix | C | -1.40 | 2 | +0.00 |
| @PrismMarketView | C | · | 2 | +0.55 |
| @stockgutter | B | -1.02 | 1 | +0.50 |
| @DekmarTrades | C | -0.59 | 1 | +0.50 |
| @HammerstoneMar3 | C | +0.30 | 1 | +0.35 |
| @doublejtrading | C | +1.73 | 1 | +0.00 |
| @aljehani | C | -1.16 | 1 | +0.50 |
| @AlertsAndNews | C | -3.92 | 1 | +0.15 |
| @OTR444 | C | +0.13 | 1 | +0.50 |
| @OpenOutcrier | C | · | 1 | +0.50 |
| @BPharmCatalyst | C | · | 1 | +0.50 |
| @SpartanTrading | C | +1.30 | 1 | +0.00 |
| @DavidScottAdams | C | -2.62 | 1 | +0.25 |
| @newsinvesting | C | · | 1 | +0.50 |
| @ClassicRoy | C | -1.10 | 1 | +0.50 |
| @PrismDM | A | -2.76 | 1 | +0.50 |
| @Tickeron | C | +1.53 | 1 | +0.50 |
| @BiopharmIQ | B | · | 1 | +0.15 |
Recent signals30of 30 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-07 | @BiopharmIQ | +0.15 | Summarizes positive midday biotech stock moves alongside company catalysts. | · | tweet ↗ |
| 2026-10-07 | @Tickeron | +0.50 | CRBU discontinued two programs, while Health Canada approved LPCN's oral testosterone therapy. | · | tweet ↗ |
| 2026-10-07 | @PrismDM | +0.50 | Health Canada approves Lipocine's TLANDO, with partner Verity planning a Canadian launch by year-end. | · | tweet ↗ |
| 2026-10-07 | @PrismMarketView | +0.50 | Health Canada approved TLANDO, with a Canadian launch planned by year-end 2026. | · | tweet ↗ |
| 2026-10-07 | @ClassicRoy | +0.50 | Watchlist cites rebounds, volume, momentum, approval, and restructuring across six stocks. | · | tweet ↗ |
| 2026-10-07 | @newsinvesting | +0.50 | Health Canada approved Lipocine's TLANDO, with a Canadian launch planned by year-end 2026. | · | tweet ↗ |
| 2026-10-07 | @PrismMarketView | +0.60 | Lists premarket gainers and decliners with percentage moves and timestamp. | · | tweet ↗ |
| 2026-10-07 | @DavidScottAdams | +0.25 | Lists five stocks as bullish morning movers. | · | tweet ↗ |
| 2026-10-07 | @SpartanTrading | +0.00 | Lists six premarket tickers being charted for an opening action plan without stating direction. | · | tweet ↗ |
| 2026-10-07 | @BPharmCatalyst | +0.50 | LPCN's partner received Health Canada approval for TLANDO, with launch planned for late 2026. | · | tweet ↗ |
| 2026-10-07 | @OpenOutcrier | +0.50 | Canada approved Lipocine's testosterone pill, with launch planned by year-end. | · | tweet ↗ |
| 2026-10-07 | @OTR444 | +0.50 | Publishes a momentum watchlist with market caps and named catalysts; output is capped at six tickers. | · | tweet ↗ |
| 2026-10-07 | @abc51648039 | +0.80 | Reports LPCN reached two prior targets and 3.99. | · | tweet ↗ |
| 2026-10-07 | @AlertsAndNews | +0.15 | Premarket gappers list identifies five stocks showing notable price moves. | · | tweet ↗ |
| 2026-10-07 | @abc51648039 | +0.20 | Lists LPCN breakout, resistance and support-break levels without explicit entry intent. | · | tweet ↗ |
| 2026-10-07 | @aljehani | +0.50 | Reports Health Canada approval of Lipocine's TLANDO and a 68% premarket gain. | · | tweet ↗ |
| 2026-10-07 | @doublejtrading | +0.00 | Publishes a broad premarket gapper watchlist without individual directions. | · | tweet ↗ |
| 2026-10-07 | @Greatstockpix | +0.00 | Morning gapper watchlist names six stocks without directional entry instructions. | · | tweet ↗ |
| 2026-10-07 | @HammerstoneMar3 | +0.35 | Lipocine's partner filed a Canadian New Drug Submission for TLANDO; shares were up 69% premarket. | · | tweet ↗ |
| 2026-10-07 | @abc51648039 | +0.20 | Lists LPCN breakout, resistance and support-break levels without explicit entry intent. | · | tweet ↗ |
| 2026-10-07 | @MrGannabc | +0.80 | Celebrates LPCN reaching three prior targets and 3.99. | · | tweet ↗ |
| 2026-10-07 | @TT_stocks_ | +0.25 | Scale out more LPCN while retaining a small runner position. — Explicitly states an ongoing scale-out while keeping a light residual position. | · | tweet ↗ |
| 2026-10-07 | @DekmarTrades | +0.50 | Lipocine received Health Canada approval for TLANDO. | · | tweet ↗ |
| 2026-10-07 | @ineedsow | +0.20 | Notes a six-candle rally and current resistance in LPCN. | · | tweet ↗ |
| 2026-10-07 | @stockgutter | +0.50 | LPCN rose sharply premarket after receiving Canadian approval. | · | tweet ↗ |
| 2026-10-07 | @Greatstockpix | +0.00 | Morning gapper watchlist names five stocks without directional entry instructions. | · | tweet ↗ |
| 2026-10-07 | @MrGannabc | +0.45 | Watchlist supplies current prices, breakout levels, support, and upside objectives. | · | tweet ↗ |
| 2026-10-07 | @TT_stocks_ | +0.30 | Scale out of LPCN as the stock rallies. — Explicitly states an ongoing scale-out during the morning ramp. | · | tweet ↗ |
| 2026-10-07 | @ineedsow | +0.20 | Contrasts ALP weakness with LPCN strength and identifies 3.22 as required support. | · | tweet ↗ |
| 2026-10-07 | @TT_stocks_ | +0.55 | Try a small LPCN position below $3 for a potential gap fill toward $7. — Suggests initiating a small position below $3 despite dilution uncertainty. | · | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.